| Pharmaceutical Information |
| Drug Name |
Peginesatide |
| Drug ID |
BADD_D01694 |
| Description |
Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012. |
| Indications and Usage |
Peginesatide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis |
| Marketing Status |
approved; investigational |
| ATC Code |
B03XA04 |
| DrugBank ID |
DB08894
|
| KEGG ID |
D09946
|
| MeSH ID |
C556270
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| UNII |
JX56W9N61Q
|
| Synonyms |
peginesatide | AF-37702 | AF 37702 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
913976-27-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
